What question did this study set out to answer?

To evaluate the efficacy of Tapestri single-cell multiomics and HemeSTAMP-MRD assays for MRD detection and clonal evolution assessment in AML.

Novel Single Cell and Bulk NGS Assays for MRD Detection and Clonal Dynamics in AML

View Full Paper

Ask AI

Bookmark

Authors

Novel assays improve MRD detection and clonal profiling in AML patients, suggesting enhanced treatment strategies.

To evaluate the efficacy of Tapestri single-cell multiomics and HemeSTAMP-MRD assays for MRD detection and clonal evolution assessment in AML.
Analyzed 72 bone marrow or peripheral blood samples from 24 AML patients.
Conducted Tapestri single-cell genotypic and immunophenotypic analysis using a 41-gene panel.
Performed HemeSTAMP-MRD on paired whole blood samples in a certified laboratory.
Compared MRD detection capabilities of Tapestri and HemeSTAMP-MRD with standard flow cytometry.
87% of patients achieved initial clinical remission, with 62.5% relapsing.
Flow cytometry detected MRD in only 33% of patients pre-relapse, whereas both assays identified MRD in 67%.
Among flow cytometry-negative cases, 4 had detectable MRD by the new assays at very low variant allele frequencies.
8 out of 9 patients showed clonal evolution between diagnosis and R/R phases.

Zhou et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark